Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials

Spotlight on Panitumumab in Metastatic Colorectal Cancer†

(2010) Gillian M. Keating   BIODRUGS

Panitumumab – an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status

(2010) Elena Elez et al.   CANCER TREATMENT REVIEWS

Panitumumab

(2010) Gillian M. Keating   DRUGS

Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations

(2010) Ezzeldin M. Ibrahim et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

(2010) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

(2010) Mario E. Lacouture et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment in advanced colorectal cancer: what, when and how?

(2009) I Chau et al.   BRITISH JOURNAL OF CANCER

Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

(2009) M. S. Banck et al.   CLINICAL CANCER RESEARCH

Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer

(2009) Eliza Hawkes et al.   Clinical Colorectal Cancer

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?

(2009) John L. Marshall   Journal of Oncology

Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone

(2008) Daniel J. Freeman et al.   Clinical Colorectal Cancer

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

(2008) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients

(2008) Rachel E Payne et al.   PHARMACOGENOMICS